Gain Therapeutics (GANX) Share-based Compensation (2020 - 2026)

Gain Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $3.9 million in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 11.09% year-over-year to $3.9 million in Q2 2026; TTM through Jun 2026 was $3.9 million, a 11.09% decrease from a year earlier, with the FY2025 full-year figure at $3.5 million, up 12.04% from the prior year.
• Share-based Compensation was $3.9 million for Q2 2026 at Gain Therapeutics, down from $4.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $4.3 million in Q2 2025, with the low at $359329.0 in Q4 2024.
• Average Share-based Compensation over 5 years is $2.5 million, with a median of $2.6 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation jumped 224.19% in 2022, then plunged 40.22% in 2024.
• Over 5 years, Share-based Compensation stood at $558692.0 in 2022, then grew by 7.59% to $601105.0 in 2023, then plunged by 40.22% to $359329.0 in 2024, then gained by 12.17% to $403046.0 in 2025, then soared by 857.36% to $3.9 million in 2026.
• The last three Share-based Compensation figures came in at $3.9 million (Q2 2026), $4.0 million (Q1 2026), and $403046.0 (Q4 2025), per Business Quant data.